Kyverna Therapeutics Inc
KYTX
Company Profile
Business description
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
Contact
5980 Horton Street
Suite 550
EmeryvilleCA94608
USAT: +1 510 925-2492
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
129
Stocks News & Analysis
stocks
Fair value lifts for toll road operator as Aussie fuel supply steadies
An Australian fuel shortage is becoming increasingly unlikely, a relief for ASX toll road operator.
stocks
Wide moat stock exchange remains cheap
Aussie stock exchange remains materially undervalued despite growing cost concerns.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,969.80 | 23.20 | 0.26% |
| CAC 40 | 8,195.70 | 12.36 | 0.15% |
| DAX 40 | 25,181.04 | 76.34 | 0.30% |
| Dow JONES (US) | 51,032.46 | 363.49 | 0.72% |
| FTSE 100 | 10,395.23 | 14.05 | -0.13% |
| HKSE | 25,398.18 | 215.79 | 0.86% |
| NASDAQ | 26,972.62 | 55.15 | 0.20% |
| Nikkei 225 | 66,934.33 | 604.83 | 0.91% |
| NZX 50 Index | 13,244.55 | 38.44 | 0.29% |
| S&P 500 | 7,580.06 | 16.43 | 0.22% |
| S&P/ASX 200 | 8,729.40 | 19.40 | 0.22% |
| SSE Composite Index | 4,057.74 | 10.83 | -0.27% |